Atlas Wealth’s Provectus Biopharmaceuticals PVCT Stock Holding History
Bought
Maintained
Sold
Other funds holding PVCT
Atlas Wealth's PVCT Position: Q3 2026 in Review
Atlas Wealth held its Provectus Biopharmaceuticals (PVCT) position steady in Q3 2026 at 19,620 shares worth $1.12K. The position accounts for ﹤0.01% of the portfolio, ranked #176.
Atlas Wealth first reported a position in PVCT in Q4 2022 and has held it in 15 quarters since. The position peaked at $6.78K in Q2 2024. 3 funds tracked by Wall St. Rank hold PVCT as of Q3 2026.
- Atlas Wealth held 19,620 shares of Provectus Biopharmaceuticals worth $1.12K as of Q3 2026.
- Atlas Wealth left its Provectus Biopharmaceuticals share count unchanged in Q3 2026.
- Provectus Biopharmaceuticals made up ﹤0.01% of Atlas Wealth's portfolio in Q3 2026, its #176 holding.
- Atlas Wealth first reported a position in Provectus Biopharmaceuticals in Q4 2022 and has held it in 15 quarters since.
- Atlas Wealth's Provectus Biopharmaceuticals position peaked at $6.78K in Q2 2024.
- 3 funds tracked by Wall St. Rank held Provectus Biopharmaceuticals as of Q3 2026.
Based on Atlas Wealth's 13F filing for Q3 2026, filed 10 Nov 2026.